The cost of VEVYE (diclofenac ophthalmic solution) 3.5% is not publicly disclosed by its manufacturer, Novaliq GmbH [1]. Information regarding the drug's pricing is typically available through channels such as pharmacy benefit managers, insurance providers, or patient assistance programs.
What is VEVYE approved for?
VEVYE is approved by the U.S. Food and Drug Administration (FDA) for the treatment of signs and symptoms of dry eye disease [2].
When was VEVYE approved?
The FDA approved VEVYE on May 22, 2023 [2].
Who makes VEVYE?
VEVYE is developed by Novaliq GmbH, a German pharmaceutical company [3].
How does VEVYE work?
VEVYE is a non-steroidal anti-inflammatory drug (NSAID) that works by reducing inflammation associated with dry eye disease [2]. Its mechanism involves inhibiting prostaglandin synthesis, which are compounds that contribute to inflammation [4].
What are the side effects of VEVYE?
The most common side effect reported for VEVYE is eye pain [2].
Are there alternative treatments for dry eye disease?
Yes, there are several alternative treatments for dry eye disease, including artificial tears, prescription eye drops like cyclosporine (Restasis) and lifitegrast (Xiidra), punctal plugs, and lifestyle modifications [5]. The choice of treatment depends on the severity and underlying cause of the dry eye condition.
When does the patent for VEVYE expire?
Information regarding the patent expiry for VEVYE is not readily available in the provided context. Patent details for pharmaceutical products can be found through resources like DrugPatentWatch.com [1].
Sources
1. https://drugpatentwatch.com/
2. https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-vevye-diclofenac-ophthalmic-solution-35-percent-treat-signs-and-symptoms-dry-eye
3. Novaliq GmbH. (n.d.). Retrieved from https://www.novaliq.com/
4. https://www.ncbi.nlm.nih.gov/books/NBK560537/
5. https://www.mayoclinic.org/diseases-conditions/dry-eyes/diagnosis-treatment/drc-20371863